Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 6/20 | 0.72 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.72 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.62 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770510 | 0.97 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1SLC6A5PLA2G4A | |
| SCHEMBL25319567 | 0.93 | SLC6A5 (0.64) | PLA2G2APLA2G5NOD1SLC6A5 | |
| SCHEMBL1893081 | 0.90 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1SLC6A5PLA2G4A | |
| SCHEMBL2770844 | 0.90 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1PLA2G4A | |
| SCHEMBL5162305 | 0.90 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1SLC6A5PLA2G4A | |
| SCHEMBL5162407 | 0.90 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1SLC6A5PLA2G4A | |
| SCHEMBL2770848 | 0.90 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1PLA2G4A | |
| SCHEMBL28306846 | 0.90 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1SLC6A5PLA2G4A | |
| SCHEMBL5501044 | 0.88 | PLA2G2A (0.74) | PLA2G2APLA2G5NOD1PLA2G4ACES2 | |
| SCHEMBL5501051 | 0.88 | PLA2G2A (0.74) | PLA2G2APLA2G5NOD1PLA2G4ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745489-B2 | Compositions and methods for inhibition of phospholipase A2 mediated inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1490328-A4 | COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION | UNIV CALIFORNIA (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20050148549-A1 | Compositions and methods for inhibition of phospholipase a2 mediated inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-07 | — | — | US | disclosed |
| EP-1490328-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION | The Regents of The University of California (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003076389-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148549-A1 | Compositions and methods for inhibition of phospholipase a2 mediated inflammation | PLA2G4A, PLA2G4B, PLA2G1B | PLA2G2A 5/4885PLA2G5 8/4885NOD1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.